重组人五聚蛋白2与安慰剂对特发性肺纤维化患者用力肺活量变化的影响:一项随机临床试验
这项2期随机双盲安慰剂对照试验在7个国家18个中心纳入117例特发性肺纤维化患者,比较重组人五聚蛋白2(10 mg/kg静脉每4周一次,n=77)与安慰剂(n=39)治疗24周的效果。主要终点为基线至第28周FVC占预计值百分比的最小二乘均值变化,重组人五聚蛋白2组为-2.5,安慰剂组为-4.8,差值+2.3(90%CI 1.1至3.5,P=0.001)。6分钟步行距离变化重组人五聚蛋白2组为-0.5 m,安慰剂组为-31.8 m,差值+31.3 m(90%CI 17.4至45.1,P<0.001)。总肺容积、HRCT定量肺实质特征及Dlco未见显著治疗差异。作者认为在这项初步研究中重组人五聚蛋白2较安慰剂延缓了肺功能下降,需进一步研究评估疗效与安全性。
要点
- 重组人五聚蛋白2组第28周FVC占预计值百分比变化-2.5 vs 安慰剂组-4.8,差值+2.3(90%CI 1.1至3.5,P=0.001),延缓了FVC下降。
- 6分钟步行距离变化重组人五聚蛋白2组-0.5 m vs 安慰剂组-31.8 m,差值+31.3 m(90%CI 17.4至45.1,P<0.001)。
- 总肺容积、HRCT定量肺实质特征(正常肺体积、间质性肺异常)及Dlco未见显著治疗差异。
- 重组人五聚蛋白2组最常见不良事件为咳嗽(18% vs 5%)、乏力(17% vs 10%)和鼻咽炎(16% vs 23%)。
- 作者认为这是初步研究,需进一步研究更全面评估疗效与安全性。
适用人群与场景
- 纳入年龄40-80岁、FVC≥50%且≤90%预计值、FEV1/FVC>0.70、Dlco≥25%且≤90%预计值、6分钟步行试验距离≥150 m的特发性肺纤维化患者(N=117)。
诊断标准与关键阈值
- 特发性肺纤维化诊断基础上,FVC≥50%且≤90%预计值、FEV1/FVC>0.70、Dlco≥25%且≤90%预计值、6分钟步行试验距离≥150 m。
- FVC占预计值百分比下降2%-6%为最小临床重要差异。
- 6分钟步行距离最小临床重要差异为24-45 m。
处置流程与药物剂量
- 重组人五聚蛋白2 10 mg/kg静脉给药,每4周一次,共24周(n=77),按是否合并特发性肺纤维化治疗分层。
- 安慰剂对照(n=39),同样每4周一次,共24周。
研究设计与关键结果
- 2期随机双盲安慰剂对照试验,7个国家18个中心,纳入117例特发性肺纤维化患者,重组人五聚蛋白2组77例、安慰剂组39例,116例至少接受1剂研究药物(平均年龄68.6岁,81.0%男性,平均诊断时间3.8年),111例(95.7%)完成研究。
- 主要终点:基线至第28周FVC占预计值百分比最小二乘均值变化,重组人五聚蛋白2组-2.5 vs 安慰剂组-4.8,差值+2.3(90%CI 1.1至3.5,P=0.001)。
- 6分钟步行距离变化:重组人五聚蛋白2组-0.5 m vs 安慰剂组-31.8 m,差值+31.3 m(90%CI 17.4至45.1,P<0.001)。
- 总肺容积差值93.5 mL(90%CI -27.7至214.7),正常肺体积差值-1.2%(90%CI -4.4至1.9),间质性肺异常差值1.1%(90%CI -2.2至4.3),Dlco差值-0.4(90%CI -2.6至1.7),均未见显著治疗差异。
- 最常见不良事件:咳嗽(重组人五聚蛋白2组18% vs 安慰剂组5%)、乏力(17% vs 10%)、鼻咽炎(16% vs 23%)。
证据类型、等级与局限
- 证据类型:2期随机双盲安慰剂对照试验。
- 作者结论:在这项初步研究中,重组人五聚蛋白2较安慰剂延缓了28周内肺功能下降,需进一步研究更全面评估疗效与安全性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在这项初步研究中,重组人五聚蛋白2较安慰剂延缓了特发性肺纤维化患者28周内FVC占预计值百分比的下降。
- 作者认为,需进一步研究更全面评估重组人五聚蛋白2的疗效与安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Approved therapies do not halt disease progression.
OBJECTIVE: To determine the effect of recombinant human pentraxin 2 vs placebo on change from baseline to week 28 in mean forced vital capacity (FVC) percentage of predicted value.
DESIGN, SETTING, AND PARTICIPANTS: Phase 2, randomized, double-blind, placebo-controlled trial conducted at 18 sites in 7 countries of eligible patients with IPF (N = 117; aged 40-80 years; FVC ≥50% and ≤90% predicted; ratio of forced expiratory volume in the first second/FVC >0.70; diffusing capacity for carbon monoxide [Dlco] ≥25% and ≤90% predicted; and distance of ≥150 m on the 6-minute walk test). Study period was August 2015-May 2017.
INTERVENTIONS: Patients were randomized to receive either recombinant human pentraxin 2 (10 mg/kg intravenous every 4 weeks, n = 77) or placebo (n = 39) for 24 weeks, and stratified by concurrent IPF treatment status.
MAIN OUTCOMES AND MEASURES: The primary end point was the least-squares mean change in FVC percentage of predicted value from baseline to week 28 (minimal clinically important difference, decline of 2%-6%). Secondary end points included mean change in lung volumes (total, normal, and interstitial lung abnormalities) on high-resolution computed tomography (HRCT) and 6-minute walk distance (minimal clinically important difference, 24-45 m).
RESULTS: Of 117 randomized patients, 116 received at least 1 dose of study drug (mean age, 68.6 years; 81.0% men; mean time since IPF diagnosis, 3.8 years), and 111 (95.7%) completed the study. The least-squares mean change in FVC percentage of predicted value from baseline to week 28 in patients treated with recombinant human pentraxin 2 was -2.5 vs -4.8 for those in the placebo group (difference, +2.3 [90% CI, 1.1 to 3.5]; P = .001). No significant treatment differences were observed in total lung volume (difference, 93.5 mL [90% CI, -27.7 to 214.7]), quantitative parenchymal features on HRCT (normal lung volume difference, -1.2% [90% CI, -4.4 to 1.9]; interstitial lung abnormalities difference, 1.1% [90% CI, -2.2 to 4.3]), or measurement of Dlco (difference, -0.4 [90% CI, -2.6 to 1.7]). The change in 6-minute walk distance was -0.5 m for patients treated with recombinant human pentraxin 2 vs -31.8 m for those in the placebo group (difference, +31.3 m [90% CI, 17.4 to 45.1]; P < .001). The most common adverse events in the recombinant human pentraxin 2 vs placebo group were cough (18% vs 5%), fatigue (17% vs 10%), and nasopharyngitis (16% vs 23%).
CONCLUSIONS AND RELEVANCE: In this preliminary study, recombinant human pentraxin 2 vs placebo resulted in a slower decline in lung function over 28 weeks for patients with idiopathic pulmonary fibrosis. Further research should more fully assess efficacy and safety.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02550873.
参考来源
- Raghu G, van den Blink B, Hamblin MJ, et al. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA. 2018. PMID: 29800034. doi:10.1001/jama.2018.6129
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。